Aim:
Patent ductus arteriosus (PDA), is one of the most common congenital cardiac anomalies in premature infants. Nonsteroidal anti-inflammatory agents are the treatment of choice for ductal closure in premature newborn. As in Iran, the only available drug is oral ibuprofen; therefore the study was conducted to determine short and long-term complications as well as the effectiveness of oral ibuprofen in the treatment of PDA in premature infants.
Including and excluding criteria:
In this clinical trial, for all preterm infants below 38 weeks admitted at Amiralmomenin Hospital, with a murmur but without any symptoms of heart failure transthoracic echocardiography was performed, and with documentation of PDA they were enrolled in the study. Infants were divided into two groups.
The neonates that have other cardiac problems except PDA ,neonates with unstable conditions, neonates with significant congenital heart disease and neonates whose mothers had taken nonsteroid anti-inflammatory substances were excluded.
In addition to the first day and the third day of treatment, a third and sixth month echocardiography were performed in both groups, and the rate of PDA closure and the rate of pulmonary hypertension in both groups were compared.The presence of intraventricular hemorrhage and periventricular leukomalacia (PVL) were detected by brain ultrasound at the age of one week and one month.
The presence of retinopathy was checked at the time of hospital discharge. Other findings such as duration of hospital stay, pulmonary hemorrhage, ventilator time dependence, duration dependence on oxygen and nosocomial infections were recorded.Then the obtained data in both groups were compared.
During 12 months all neonates with the above criteria are included and a total number of 60 neoantes will be studied.